(NASDAQ: BDSX) Biodesix's forecast annual revenue growth rate of 17.48% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 9.2%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.71%.
Biodesix's revenue in 2026 is $96,096,000.On average, 7 Wall Street analysts forecast BDSX's revenue for 2026 to be $1,120,536,093, with the lowest BDSX revenue forecast at $1,066,960,619, and the highest BDSX revenue forecast at $1,158,038,925. On average, 7 Wall Street analysts forecast BDSX's revenue for 2027 to be $1,335,141,246, with the lowest BDSX revenue forecast at $1,268,020,275, and the highest BDSX revenue forecast at $1,386,189,575.
In 2028, BDSX is forecast to generate $1,568,245,101 in revenue, with the lowest revenue forecast at $1,483,939,544 and the highest revenue forecast at $1,638,802,990.